fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

International Clinical Trials Day

20/ 05/ 2025
  For over three years, the clinical trials industry in Ukraine has been operating under extremely challenging conditions due to russia’s full-scale war against Ukraine. Yet the resilience, professionalism, and dignity shown by everyone involved in this field are inspiring. Sponsors, contract research organizations, logistics providers — despite all existing threats — remain loyal to patients and to science. They continue running studies, supporting their teams, preserving jobs, investing in the country, and paying taxes. Investigators and doctors maintain the high quality of clinical trials, pursue professional development, and implement new knowledge, medical technologies, and innovations. And patients — despite all the challenges — do not lose hope, strength, or their desire to live. We are sincerely grateful to our partners — Members of Parliament, the Ministry of Health of Ukraine, the State Expert Center, and the State Service on Medicines and Drugs Control — with whom we stand side by side to secure Ukraine’s place in the international research landscape. Thank you for your openness to cooperation and joint work to create a supportive regulatory environment for the recovery and growth of clinical trials in Ukraine. Every legislative update that removes barriers to conducting trials in Ukraine, and every approved protocol, brings not only investment in science and the economy, but also someone’s chance for recovery. The Clinical Trials Subcommittee of the European Business Association thanks the entire community for your trust, professionalism, and resilience. We will keep moving forward — for the restoration of clinical trials, the advancement of innovation, and for those who are still waiting for treatment.

For over three years, the clinical trials industry in Ukraine has been operating under extremely challenging conditions due to russia’s full-scale war against Ukraine. Yet the resilience, professionalism, and dignity shown by everyone involved in this field are inspiring.

Sponsors, contract research organizations, logistics providers — despite all existing threats — remain loyal to patients and to science. They continue running studies, supporting their teams, preserving jobs, investing in the country, and paying taxes. Investigators and doctors maintain the high quality of clinical trials, pursue professional development, and implement new knowledge, medical technologies, and innovations. And patients — despite all the challenges — do not lose hope, strength, or their desire to live.

We are sincerely grateful to our partners — Members of Parliament, the Ministry of Health of Ukraine, the State Expert Center, and the State Service on Medicines and Drugs Control — with whom we stand side by side to secure Ukraine’s place in the international research landscape. Thank you for your openness to cooperation and joint work to create a supportive regulatory environment for the recovery and growth of clinical trials in Ukraine. Every legislative update that removes barriers to conducting trials in Ukraine, and every approved protocol, brings not only investment in science and the economy, but also someone’s chance for recovery.

The Clinical Trials Subcommittee of the European Business Association thanks the entire community for your trust, professionalism, and resilience. We will keep moving forward — for the restoration of clinical trials, the advancement of innovation, and for those who are still waiting for treatment.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks

Spelling error report

The following text will be sent to our editors: